Colonic drug delivery can facilitate access to unique therapeutic targets and has the
potential to enhance drug bioavailability whilst reducing off-target effects. Delivering drugs to …

Protein and peptide therapeutics require parenteral administration, which can be a deterrent
to medication adherence. For this reason, there have been extensive efforts to develop …

Gastrointestinal-based drug delivery is considered the preferred mode of drug
administration owing to its convenience for patients, which improves adherence. However …

Throughout history, oral administration has been regarded as the most convenient mode of
drug delivery, as it requires minimal expertise and invasiveness. Although oral delivery …

Proteins and peptides (PPs) have gradually become more attractive therapeutic molecules
than small molecular drugs due to their high selectivity and efficacy, but fewer side effects …

In its 33 years, ADDR has published regularly on the po5tential of oral delivery of biologics
especially peptides and proteins. In the intervening period, analysis of the preclinical and …

Semaglutide, a glucagon like peptide-1 (GLP-1) receptor agonist, is available as
monotherapy in both subcutaneous as well as oral dosage form (first approved oral GLP-1 …

Inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) reduce low-density
lipoprotein (LDL) cholesterol and are used for treatment of dyslipidemia. Current PCSK9 …

Intercellular tight junctions represent a formidable barrier against paracellular drug
absorption at epithelia (eg, nasal, intestinal) and the endothelium (eg, blood–brain barrier) …

Bovine milk-derived exosomes have recently emerged as a promising nano-vehicle for the
encapsulation and delivery of macromolecular biotherapeutics. Here we engineer high …